open access

Vol 3, No 1 (2007)
Review paper
Published online: 2007-01-12
Get Citation

Postoperative radio-chemotherapy - a new standard in treatment for glioblastoma?

Małgorzata Klonowicz, Michał Spych, Jacek Fijuth
Onkol. Prak. Klin 2007;3(1):28-31.

open access

Vol 3, No 1 (2007)
REVIEW ARTICLES
Published online: 2007-01-12

Abstract

A median survival in patients with glioblastoma multiforme after surgical resection and high dose radiation therapy is less than 1 year. Promising prospects in treatment these patients create phase III multicenter trials with concomitant usage of postoperative radiochemotherapy with themozolomid. This is an orally administered alkylating agent, that is able to cross the blood-brain barrier. In this agent case alkylation is the transfer of an alkyl group (in this particular case - methyl group) to the DNA and it usually concern a guanine as a target. The DNA-repair enzyme - O6-methylguanine-DNA methyltransferase (MGMT) removes a methyl group from methylated guanine and that way possibly inhibits the killing of tumor cells by alkylating agents. Methylation of the MGMT’s promoter makes impossible to procced with transcription, and the same inhibits producing of MGMT. It may results in lack of DNA repair which is alkylated by agent and the same may be associated with longer survival in patients with glioblastoma.

Abstract

A median survival in patients with glioblastoma multiforme after surgical resection and high dose radiation therapy is less than 1 year. Promising prospects in treatment these patients create phase III multicenter trials with concomitant usage of postoperative radiochemotherapy with themozolomid. This is an orally administered alkylating agent, that is able to cross the blood-brain barrier. In this agent case alkylation is the transfer of an alkyl group (in this particular case - methyl group) to the DNA and it usually concern a guanine as a target. The DNA-repair enzyme - O6-methylguanine-DNA methyltransferase (MGMT) removes a methyl group from methylated guanine and that way possibly inhibits the killing of tumor cells by alkylating agents. Methylation of the MGMT’s promoter makes impossible to procced with transcription, and the same inhibits producing of MGMT. It may results in lack of DNA repair which is alkylated by agent and the same may be associated with longer survival in patients with glioblastoma.
Get Citation

Keywords

glioblastoma multiforme; radiation therapy; temozolomid; MGMT

About this article
Title

Postoperative radio-chemotherapy - a new standard in treatment for glioblastoma?

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 1 (2007)

Article type

Review paper

Pages

28-31

Published online

2007-01-12

Bibliographic record

Onkol. Prak. Klin 2007;3(1):28-31.

Keywords

glioblastoma multiforme
radiation therapy
temozolomid
MGMT

Authors

Małgorzata Klonowicz
Michał Spych
Jacek Fijuth

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl